LAG3 and neoplasm: The anti-LAG3/PD-L1/Paclitaxel treatment showed the most significant metastasis reduction from tumors with NF1, TSC1, or TβRII inactivation but not from the 4T1-C1 control tumor (Fig. 7E and Fig. S6B).